Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Kirkpatrick

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Nature Biotechnology|February 7, 2015
Incubators for innovatorsLynn Kirkpatrick
Molecular Cancer Therapeutics|May 14, 2004
Hypoxia inducible factor-1alpha as a cancer drug targetGarth Powis, Lynn Kirkpatrick
Antioxidants & Redox Signaling|March 18, 2016
Clinically Evaluated Cancer Drugs Inhibiting Redox SignalingD Lynn Kirkpatrick, Garth Powis
Current Opinion in Pharmacology|July 6, 2007
Thioredoxin signaling as a target for cancer therapyGarth Powis, D Lynn Kirkpatrick
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathwayGarth Powis, Nathan Ihle, D Lynn Kirkpatrick
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 3, 2023
Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human diseaseGarth Powis, Emmanuelle J Meuillet, Martin Indarte, et al.
Journal of Pharmaceutical Sciences|July 13, 2002
Solubility, ionization, and partitioning behavior of unsymmetrical disulfide compounds: alkyl 2-imidazolyl disulfidesAhmad Hashash, D Lynn Kirkpatrick, John S Lazo, et al.
Molecular Cancer Therapeutics|March 18, 2004
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alphaSarah Welsh, Ryan Williams, Lynn Kirkpatrick, et al.
Molecular Cancer Therapeutics|March 21, 2006
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductaseGarth Powis, Peter Wipf, Stephen M Lynch, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|March 13, 2002
Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfideAhmad Hashash, D Lynn Kirkpatrick, Merrill J Egorin, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Nature Biotechnology|February 7, 2015
Incubators for innovatorsLynn Kirkpatrick
Molecular Cancer Therapeutics|May 14, 2004
Hypoxia inducible factor-1alpha as a cancer drug targetGarth Powis, Lynn Kirkpatrick
Antioxidants & Redox Signaling|March 18, 2016
Clinically Evaluated Cancer Drugs Inhibiting Redox SignalingD Lynn Kirkpatrick, Garth Powis
Current Opinion in Pharmacology|July 6, 2007
Thioredoxin signaling as a target for cancer therapyGarth Powis, D Lynn Kirkpatrick
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathwayGarth Powis, Nathan Ihle, D Lynn Kirkpatrick
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 3, 2023
Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human diseaseGarth Powis, Emmanuelle J Meuillet, Martin Indarte, et al.
Journal of Pharmaceutical Sciences|July 13, 2002
Solubility, ionization, and partitioning behavior of unsymmetrical disulfide compounds: alkyl 2-imidazolyl disulfidesAhmad Hashash, D Lynn Kirkpatrick, John S Lazo, et al.
Molecular Cancer Therapeutics|March 18, 2004
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alphaSarah Welsh, Ryan Williams, Lynn Kirkpatrick, et al.
Molecular Cancer Therapeutics|March 21, 2006
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductaseGarth Powis, Peter Wipf, Stephen M Lynch, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|March 13, 2002
Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfideAhmad Hashash, D Lynn Kirkpatrick, Merrill J Egorin, et al.
Pageof 4